Hancock Jaffe Laboratories, Inc. Stock

$1.00

3.09% today

Nasdaq, Aug 22, 10:15 pm CET

ISIN

US41015N1063

Symbol

NVNO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Hancock Jaffe Laboratories, Inc. Stock price

$1.00

-8.88 89.87% 5Y

Nasdaq, Closing price Fri, Aug 22 2025

+0.03 3.09%

ISIN

US41015N1063

Symbol

NVNO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$18.7m

Enterprise Value

$-16.5m

Net debt

positive

Cash

$35.1m

Shares outstanding

19.3m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

1.0

P/B

0.6

Financial Health

Equity Ratio

93.8%

Return on Equity

-52.2%

ROCE

-74.1%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-24.4m | -

EBIT

$-24.9m | $-24.2m

Net Income

$-23.1m | $-21.2m

Free Cash Flow

$-17.1m

EPS

$-1.1

FCF per Share

$-0.9

Short interest

2.9%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

Hancock Jaffe Laboratories, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Hancock Jaffe Laboratories, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Hancock Jaffe Laboratories, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Hancock Jaffe Laboratories, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	13 13	20% 20% -
- Research and Development Expense	12 12	1% 1% -
EBITDA	-24 -24	10% 10% -
- Depreciation and Amortization	0.50 0.50	28% 28% -
EBIT (Operating Income) EBIT	-25 -25	10% 10% -
Net Profit	-23 -23	12% 12% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Hancock Jaffe Laboratories, Inc. Stock News

Neutral

Accesswire

●

2 days ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

IRVINE, CA / ACCESS Newswire / August 20, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received a not-approvable letter from the U.S. Food & Drug Administration (FDA) in response to its Premarket Approval (PMA) application for VenoValve®, a surgical rep...

Neutral

Accesswire

●

7 days ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

- Live webcast on Thursday, August 21stat 2:00 PM ET IRVINE, CA / ACCESS Newswire / August 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19...

Neutral

Accesswire

●

16 days ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatments The VenoValve could potentially save $5.9 billion annually in healthcare costs for the approximately 2.5 million U.S. patients with severe CVI Company to host live webcast with lead author of the cost-analysis manuscri...

More Hancock Jaffe Laboratories, Inc. News

Company Profile

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Head office	United States
CEO	Robert Berman
Employees	37
Founded	1999
Website	envveno.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now